The historical rank and industry rank for Rigel Pharmaceuticals's PB Ratio or its related term are showing as below:
FRA:RI2'
s PB Ratio Range Over the Past 10 Years
Min: 1.2 Med: 5.45 Max: 123.98
Current: 1.72
During the past 13 years, Rigel Pharmaceuticals's highest PB Ratio was 123.98. The lowest was 1.20. And the median was 5.45.
FRA:RI2's PB Ratio is ranked better than 68.94% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs FRA:RI2: 1.72
During the past 12 months, Rigel Pharmaceuticals's average Book Value Per Share Growth Rate was 1982.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Rigel Pharmaceuticals was 203.30% per year. The lowest was -52.80% per year. And the median was -15.20% per year.
Back to Basics: PB Ratio
Rigel Pharmaceuticals (FRA:RI2) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rigel Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Rigel Pharmaceuticals (FRA:RI2) has a PB Ratio of 1.64 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rigel Pharmaceuticals and its competitors. This is 70% below median its historical median of 5.45. Over the past decade, Rigel Pharmaceuticals' PB Ratio has ranged from 1.20 to 123.98. According to the industry distribution chart, Rigel Pharmaceuticals ranks #383 out of 1233 companies in the Biotechnology industry, placing it in the top 31.1%.
Is Rigel Pharmaceuticals' PB Ratio too high?
Rigel Pharmaceuticals' current PB Ratio of 1.64 is 70% below median its 10-year median of 5.45. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 123.98. The Biotechnology industry median PB Ratio is 2.83. Rigel Pharmaceuticals' value of 1.64 is 42% below this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #383 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' PB Ratio compare to CBIO and TRAX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #383 out of 1233 companies for PB Ratio. This puts Rigel Pharmaceuticals in the upper half of its industry. The industry median PB Ratio is 2.83. Rigel Pharmaceuticals' value of 1.64 is 42% below this benchmark. Historically, Rigel Pharmaceuticals' own PB Ratio has ranged from 1.20 to 123.98 over the past decade. While the company's 10-year median is 5.45 vs. the industry median of 2.83, Rigel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current PB Ratio of 1.64 is 42% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current PB Ratio is 1.64, which is 70% below median its own 10-year median of 5.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current PB Ratio of 1.64. The stock's GF Value™ is €23.45, compared to a current price of €30.77 — trading 31.2% above its estimated fair value. The current PB Ratio is 1.64, which is 70% below median its 10-year median of 5.45 and 42% below the Biotechnology industry median of 2.83. Rigel Pharmaceuticals' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current PB Ratio is 1.64 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €30.77 is trading 31.2% above its estimated GF Value™ of €23.45.
Key valuation signals for FRA:RI2:
PB Ratio: 1.64 (70% below median its 10-year median of 5.45)
GF Value™: €23.45 vs. price of €30.77 (31.2% above fair value)
Industry Position: 42% below the Biotechnology median (#383 of 1233)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
78GF Score
Get the complete analysis for FRA:RI2
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
